Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients
NCT02531412Phase 3Unknown
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney injury (AKI) comparing Spironolactone with Placebo (2 arms). Primary endpoints: Acute kidney injury by 0.3 creatinine elevation at 48 hours, Acute kidney injury by 1.5 times creatinine elevation at 48 hours and 1 more. Status: unknown.
02
Drugs
spironolactone
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02531412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531412.